Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $58.0 million.

  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average) rose 205.01% to $58.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.0 million, marking a year-over-year increase of 205.01%. This contributed to the annual value of $58.0 million for FY2025, which is 205.01% up from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) is $58.0 million, which was up 205.01% from $58.1 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $69.5 million in Q1 2021 and a low of $54.6 million during Q1 2022
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $56.8 million (2024), whereas its average is $57.9 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 2155.2% in 2022, and later skyrocketed by 215.49% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $60.4 million in 2021, then decreased by 9.36% to $54.8 million in 2022, then increased by 1.57% to $55.7 million in 2023, then rose by 2.08% to $56.8 million in 2024, then rose by 2.05% to $58.0 million in 2025.
  • Its last three reported values are $58.0 million in Q4 2025, $58.1 million for Q3 2025, and $57.9 million during Q2 2025.